

01-17-2002

F

MMD  
1-9-02



101951815

To the Honorable Commissioner of Patents and Trademarks

Attached original documents or copy thereof

1. Submission Type:  **NEW**

New

Resubmission (Non-Recordation)

Document ID# \_\_\_\_\_

Correction of PTO Error

Reel # \_\_\_\_\_ Frame # \_\_\_\_\_

Corrective Document

Reel # \_\_\_\_\_ Frame # \_\_\_\_\_

Data Element in Question: \_\_\_\_\_

Type:  Assignment  Security Agreement


License  Change of Name

Merger  Other \_\_\_\_\_

US. GOVERNMENT  
(For Use ONLY by U.S. Government Agencies)

Departmental File  Secret File

Total No. of pages of conveyance document including attachments: \_\_\_\_\_



4. Name of conveying party(ies):

- Patrick Y. Lam
- Qi Han
- Charles G. Clark
- Thomas E. Richardson

Additional name(s) of conveying party(ies) attached?  Yes  No

Execution Date: **October 31, 2001**

5. Name and address of receiving party(ies):

Bristol-Myers Squibb Pharma Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000

Additional name(s) & address(es) attached?  Yes  No

6. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s): **09/898,279**  
Docket No.: **PH-7075-A**

B. Patent No.(s): \_\_\_\_\_

Additional numbers attached:  Yes  No

7. Correspondent Name & Address:

**DAVID J. ROPER  
BRISTOL-MYERS SQUIBB PHARMA COMPANY  
974 CENTRE ROAD  
CHESTNUT RUN PLAZA  
WILMINGTON, DE 19805**

8. Total number of applications and patents involved: 1

9. Total fee (37 CFR 3.41) ..... \$40.00

Enclosed (Check No.: \_\_\_\_\_)

Authorized to be charged to deposit account

10. Deposit account number: 023850  
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

11. Statement and signature.  
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Cathleen M. Collins \_\_\_\_\_ 11-2-01  
Signature Date

Cathleen M. Collins, Legal Secretary

Total number of pages comprising cover sheet: 1

01/17/2002 LHWELLER 00000003 023850 09898279  
01 FC:581 40.00 CH

PATENT APPLICATION ASSIGNMENT

We, the undersigned

Hereby declare that

We are the true and first inventors of an invention entitled Imidazo Heterobicycles as Factor Xa Inhibitors (and which is identified as Case Number PH-7075-A) and which is disclosed in an application for Letters Patent in the United States of America.

For valuable consideration, the receipt and adequacy of which is hereby acknowledged and in fulfillment of our pre-existing obligation of assignment, we hereby:

I. Sell, assign, and transfer unto **DuPont Pharmaceuticals Company**, a General Partnership organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805, hereinafter referred to as the assignee, (A). the sole and entire right, and interest in and to: (1) the aforesaid application for Letters Patent, (2) any priority rights derived from the aforesaid application for Letters Patent by virtue of intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, (3) any and all of our inventions, whether joint or sole, disclosed in the aforesaid application for Letters Patent, (4) any and all applications for Letters Patent for any such inventions in any country whatsoever, (5) any and all patents for any such inventions in any country whatsoever; and (B) the sole right to (1) file such applications in its name or ours, (2) file such applications under the aforesaid International Convention or other treaty or understanding, (3) have said patents granted in its name or ours, and (4) enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future; and

II. Agree, whenever requested, to communicate to said assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers or instruments necessary or required by said assignee, its successors, assigns and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid said assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

We further authorize our attorney/patent agent to insert below\* the application number and filing date of the aforesaid United States application now identified as Case Number. After the same shall have been made known to him/her by the United States Patent Office.

Date: 10/4/01  
Patrick Y. Lam (L.S.)  
Patrick Y. Lam

Date: 4-Oct-2001  
Charles G. Clark (L.S.)  
Charles G. Clark

Date: 10/5/01  
Qi Han (L.S.)  
Qi Han

Date: 9/25/01  
Thomas E. Richardson (L.S.)  
Thomas E. Richardson

\*The application referred to above (Case No. PH-7075-A) was filed in the United States Patent Office on July 3, 2001, and was given Application No. 09/898,279.  
This insertion made by me this 31<sup>st</sup> day of October, 2001.

David J. Roper  
David J. Roper Attorney for Applicants